News Rumour of Pfizer, Seagen deal is true, with $43bn price tag Pfizer says Seagen's current and future drugs could add $10 billion to its revenues from 2030.
News Despite FDA doubts, advisors back first-line Polivy use Panel votes 11 to 2 to back Roche's drug for treatment-naïve diffuse large B-cell lymphoma.
R&D Allogeneic therapies: The future of cancer treatment? Allogeneic therapies could provide an answer to some of the drawbacks of autologous therapies.
News Could VR therapy improve mental health in cancer patients? Study is testing a VR DTx developed by Rocket VR Health and Massachusetts General Hospital.
News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
News FDA removes leash from Verzenio in early breast cancer Drug can now be used as adjuvant therapy without Ki-67 testing, taking a brake off prescribing.
R&D Treating the chronic diseases GLP-1s miss, with Laurent Auda... Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
